Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$18.04 – $25.99
57% from low
Exchange
OTC Link
ADRC
Borrow rate
4.46%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.26B | $9.28B | $8.53B | $9.59B | $10.85B | $10.67B | $10.71B | $9.76B |
| Cost of revenue | $5.33B | $5.31B | $4.75B | $5.73B | $6.92B | $6.43B | $6.37B | $5.87B |
| Gross profit | $3.93B | $3.97B | $3.79B | $3.85B | $3.92B | $4.23B | $4.34B | $3.89B |
| Gross margin | 42.4% | 42.8% | 44.4% | 40.2% | 36.2% | 39.7% | 40.5% | 39.9% |
| R&D | $58.0M | $255.0M | $238.0M | $230.0M | $258.0M | $270.0M | $296.0M | $0 |
| Operating income | $605.0M | $841.0M | $963.0M | $1.12B | $708.0M | $1.03B | $917.0M | $743.5M |
| EBITDA | $854.0M | $1.26B | $1.33B | $1.53B | $1.05B | $1.33B | $1.40B | $1.48B |
| Net income | $6.67B | $539.0M | $630.0M | $829.0M | $352.0M | $442.0M | $542.0M | $609.9M |
| Net margin | 72.1% | 5.8% | 7.4% | 8.6% | 3.2% | 4.1% | 5.1% | 6.3% |
| EPS (diluted) | 9.78 | 0.81 | 1.09 | 1.49 | 0.67 | 0.86 | 1.05 | 1.23 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10.2B | $1.32 | $1.29–$1.35 | 2 |
| 2027 | $10.5B | $1.46 | $1.41–$1.51 | 2 |
| 2028 | $10.6B | $1.57 | $1.53–$1.61 | 1 |
| 2029 | $11.1B | $1.80 | $1.76–$1.85 | 1 |
Forward consensus · source: Financial Modeling Prep
AKZO NOBEL N V S/ADR
No one on the platform currently holds AKZOY.
No tracked institution reports a position in AKZOY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-28 | $0.6036 | 2026-05-13 |
| 2025-11-03 | $0.1692 | 2025-11-13 |
| 2025-04-30 | $0.5835 | 2025-05-14 |
| 2024-11-07 | $0.1583 | 2024-11-15 |
| 2024-04-29 | $0.5529 | 2024-05-14 |
| 2023-11-03 | $0.1571 | 2023-11-16 |
| Execution date | Ratio |
|---|---|
| 2019-01-24 | 8-for-9reverse |
No one on the platform has traded AKZOY yet.
| $39.3B |
| — |
| NVZMFNovozymes A/S | $63.02 | +4.00% | $29.4B | — |
| NVZMYNovozymes A/S | $63.18 | -0.09% | $29.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 24.8× earnings vs its 24.7× historical median P/E.
Fair value ≈ $22.44 · price $22.54 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.